Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Apr;84(4):853–860. doi: 10.1111/j.1476-5381.1985.tb17379.x

Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis.

F Brown, W Campbell, P J Mitchell, K Randall
PMCID: PMC1987050  PMID: 4005487

Abstract

Criteria for distinguishing dopamine autoreceptor agonism from other mechanisms of inhibiting locomotion were examined, together with the relationship between inhibition of locomotion and dopamine synthesis. ED50 potencies to inhibit locomotion of mice were established for drugs from a number of categories. Spiperone 0.02 mg kg-1 significantly (P less than 0.05) reversed inhibition of locomotion by known dopamine agonists but not that by the other types of drug. Idazoxan antagonized inhibition of locomotion due to alpha 2-agonists but not dopamine agonists. RU 24926 (N-propyl-N,N-di[2-(3-hydroxyphenyl)ethyl]amine) was antagonized by both spiperone and idazoxan. Only for dopamine agonists was there good correlation (r = 0.97) between potencies to inhibit locomotion in mice and L-dihydroxyphenylalanine (L-DOPA) accumulation in the nucleus accumbens of rats treated with gamma-butyrolactone and 3-hydroxybenzylhydrazine. The specific dopamine D1-agonist, SK&F 38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine), was inactive in both tests at doses up to 10 mg kg-1. The mixed dopamine agonist/antagonist, (-)-3-(3-hydroxyphenyl)-N-propylpiperidine, commonly known as (-)-3-PPP, acted as a dopamine agonist in both tests but inhibited locomotion more potently than L-DOPA accumulation. The inhibitory effects of dopamine agonists on locomotion were not prevented by alpha-methyl-p-tyrosine pretreatment. The data suggest that spiperone-reversible inhibition of locomotion in mice is a good criterion for dopamine autoreceptor agonists. The receptors involved are affected by low doses of both dopamine agonists and antagonists and seem similar to those involved in the autoreceptor mediated inhibition of dopamine synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
853

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andén N. E., Nilsson H., Ros E., Thornström U. Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol Toxicol (Copenh) 1983 Jan;52(1):51–56. doi: 10.1111/j.1600-0773.1983.tb01075.x. [DOI] [PubMed] [Google Scholar]
  2. Costall B., Lim S. K., Naylor R. J. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice. Eur J Pharmacol. 1981 Jul 17;73(2-3):175–188. doi: 10.1016/0014-2999(81)90089-3. [DOI] [PubMed] [Google Scholar]
  3. Di Chiara G., Porceddu M. L., Vargiu L., Argiolas A., Gessa G. L. Evidence for dopamine receptors mediating sedation in the mouse brain. Nature. 1976 Dec 9;264(5586):564–567. doi: 10.1038/264564a0. [DOI] [PubMed] [Google Scholar]
  4. Doxey J. C., Lane A. C., Roach A. G., Virdee N. K. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol. 1984 Feb;325(2):136–144. doi: 10.1007/BF00506193. [DOI] [PubMed] [Google Scholar]
  5. Euvrard C., Ferland L., Di Paolo T., Beaulieu M., Labrie F., Oberlander C., Raynaud J. P., Boissier J. R. Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology. 1980 Apr;19(4):379–386. doi: 10.1016/0028-3908(80)90190-2. [DOI] [PubMed] [Google Scholar]
  6. Farnebo L. O., Hamberger B. Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices. Acta Physiol Scand Suppl. 1971;371:35–44. doi: 10.1111/j.1748-1716.1971.tb05213.x. [DOI] [PubMed] [Google Scholar]
  7. Grigoriadis D., Seeman P. The dopamine/neuroleptic receptor. Can J Neurol Sci. 1984 Feb;11(1 Suppl):108–113. doi: 10.1017/s0317167100046242. [DOI] [PubMed] [Google Scholar]
  8. Haubrich D. R., Pflueger A. B. The autoreceptor control of dopamine synthesis. An in vitro and in vivo comparison of dopamine agonists. Mol Pharmacol. 1982 Jan;21(1):114–120. [PubMed] [Google Scholar]
  9. Hjorth S., Carlsson A., Clark D., Svensson K., Wikström H., Sanchez D., Lindberg P., Hacksell U., Arvidsson L. E., Johansson A. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) 1983;81(2):89–99. doi: 10.1007/BF00428999. [DOI] [PubMed] [Google Scholar]
  10. Hunkeler W., Möhler H., Pieri L., Polc P., Bonetti E. P., Cumin R., Schaffner R., Haefely W. Selective antagonists of benzodiazepines. Nature. 1981 Apr 9;290(5806):514–516. doi: 10.1038/290514a0. [DOI] [PubMed] [Google Scholar]
  11. Raiteri M., Cervoni A. M., del Carmine R., Levi G. Do presynaptic autoreceptors control dopamine release? Nature. 1978 Aug 17;274(5672):706–708. doi: 10.1038/274706a0. [DOI] [PubMed] [Google Scholar]
  12. Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed] [Google Scholar]
  13. Setler P. E., Sarau H. M., Zirkle C. L., Saunders H. L. The central effects of a novel dopamine agonist. Eur J Pharmacol. 1978 Aug 15;50(4):419–430. doi: 10.1016/0014-2999(78)90148-6. [DOI] [PubMed] [Google Scholar]
  14. Strömbom U. Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(2):167–176. doi: 10.1007/BF00498588. [DOI] [PubMed] [Google Scholar]
  15. Walters J. R., Roth R. H. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol. 1976 Dec;296(1):5–14. doi: 10.1007/BF00498834. [DOI] [PubMed] [Google Scholar]
  16. Westerink B. H., Mulder T. B. Determination of picomole amounts of dopamine, noradrenaline, 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindolacetic acid in nervous tissue after one-step purification on Sephadex G-10, using high-performance liquid chromatography with a novel type of electrochemical detection. J Neurochem. 1981 Apr;36(4):1449–1462. doi: 10.1111/j.1471-4159.1981.tb00586.x. [DOI] [PubMed] [Google Scholar]
  17. Wreggett K. A., De Léan A. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. Mol Pharmacol. 1984 Sep;26(2):214–227. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES